MESO250117P2000
- 0.10
- 0.000.00%
Mesoblast Newsroom
This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
Jefferies Downgrades Mesoblast to Hold From Buy; Price Target Is AU$2.30
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Maintains Target Price $30
Maxim Group Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $30
Piper Sandler Maintains Mesoblast(MESO.US) With Buy Rating, Raises Target Price to $15
US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
ISCT Hails Landmark US FDA Approval of RYONCIL as Major Milestone for MSC Field
Mesoblast Director Increases Stake With Major Share Acquisition
Mesoblast Limited Expands Equity With New Share Quotation
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Mesoblast MESO Approval; Sangamo SGMO Astellas Pharma ALPMY Licensing Deal
What's Going On With Mesoblast Shares Thursday?
Mesoblast Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Overweight on Mesoblast, Raises Price Target to $15
Mesoblast Analyst Ratings
MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Pluri Shares Are Trading Higher After the Company Announced FDA Approval for Mesoblast.
Sector Update: Health Care Stocks Mixed Premarket Thursday